scholarly journals Biphasic Expression of Atypical Chemokine Receptor (ACKR) 2 and ACKR4 in Colorectal Neoplasms in Association with Histopathological Findings

Biomolecules ◽  
2020 ◽  
Vol 11 (1) ◽  
pp. 8
Author(s):  
Paulina Lewandowska ◽  
Jaroslaw Wierzbicki ◽  
Marek Zawadzki ◽  
Anil Agrawal ◽  
Małgorzata Krzystek-Korpacka

Facilitating resolution of inflammation using atypical chemokine receptors (ACKR) as an anticancer strategy is considered but requires a deeper understanding of receptor role in carcinogenesis. We aimed at transcriptional analysis (RTqPCR) of ACKR2 and ACKR4 expression in colorectal adenoma-adenocarcinoma sequence in paired normal-neoplastic tissues from 96 polyps and 51 cancers. On average, ACKR2 was downregulated in neoplastic as compared to non-affected tissue in polyp (by 2.7-fold) and cancer (by 3.1-fold) patients. The maximal downregulation (by 8.2-fold) was observed in adenomas with the highest potential for malignancy and was gradually lessening through cancer stages I-IV, owing to increased receptor expression in tumors. On average, ACKR4 was significantly downregulated solely in adenocarcinomas (by 1.5-fold), less so in patients with lymph node metastasis, owing to a gradual decrease in ACKR4 expression among N0-N1-N2 cancers in non-affected tissue without changes in tumors. In adenomas, ACKR4 downregulation in neoplastic tissue increased with increasing potential for malignancy and contribution of villous growth pattern. ACKR4 expression increased in non-affected tissue with a concomitant decrease in pathological mucosa. In conclusion, the changes in ACKRs expression occur already in precancerous colorectal lesions, culminating in the adenomas with the highest potential for malignancy. Therefore, chemoprevention by manipulating ACKRs’ expression is worth exploration.

HPB ◽  
2017 ◽  
Vol 19 ◽  
pp. S20-S21
Author(s):  
Yohsuke Yagawa ◽  
Atsushi Aruga ◽  
Nobuhiro Takeshita ◽  
Ryota Higuchi ◽  
Takahisa Yazawa ◽  
...  

2015 ◽  
Vol 3 (6) ◽  
pp. 1229-1232 ◽  
Author(s):  
HONG XIAN WANG ◽  
LIN YU TAO ◽  
KE QI ◽  
HAO YUN ZHANG ◽  
DUO FENG ◽  
...  

2020 ◽  
Vol 8 (A) ◽  
pp. 818-823
Author(s):  
Bhayu Chandra Purnomo ◽  
Birgitta M. Dewayani ◽  
Sri Suryanti ◽  
Bethy S. Hernowo

BACKGROUND: Squamous cell carcinoma (SCC) is the most common type of cervical cancer. Pelvic lymph node metastasis in cervical SCC is common. Programmed death ligand 1 (PD-L1) on tumor cells has been reported to impede anti-tumor immunity, resulting in immune evasion. C-X-C chemokine receptor type 4 (CXCR4) plays an important role in proliferation, survival, and migration (chemotaxis) of tumor cells. AIM: This study aimed to analyze the association of PD-L1 and CXCR4 immunoexpression with pelvic lymph node metastasis in cervical SCC. MATERIALS AND METHODS: Forty cases of cervical SCC in the Department of Anatomical Pathology, Faculty of Medicine, Padjadjaran University, Dr. Hasan Sadikin Hospital, Bandung, during 2013–2018 were collected and divided into two groups; (1) cervical SCC metastasize to pelvic lymph node and (2) cervical SCC non-metastasize to pelvic lymph node, of 20 cases, respectively. The expression of PD-L1 and CXCR4 was detected using immunohistochemistry. RESULTS: High immunoexpression of PD-L1 and CXCR4 in cervical SCC showed significant association with pelvic lymph node metastasis (p < 0.05). The stepwise logistic regression analysis revealed that both PD-L1 and CXCR4 immunoexpression influenced pelvic lymph node metastasis simultaneously. CONCLUSION: It could be concluded that the higher PD-L1 and CXCR4 immunoexpression showed the higher ability of tumor cells to metastasize to the pelvic lymph node.


Pancreas ◽  
2016 ◽  
Vol 45 (8) ◽  
pp. 1167-1174 ◽  
Author(s):  
Alexander Muckenhuber ◽  
Galina Babitzki ◽  
Marlene Thomas ◽  
Gabriele Hölzlwimmer ◽  
Magdalena Zajac ◽  
...  

Head & Neck ◽  
2005 ◽  
Vol 27 (12) ◽  
pp. 1049-1055 ◽  
Author(s):  
Dubravka S. Cvejic ◽  
Svetlana B. Savin ◽  
Ivana M. Petrovic ◽  
Ivan R. Paunovic ◽  
Svetislav B. Tatic ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document